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ABSTRACT
Background: Acute exacerbation chronic obstructive pulmonary disease (AECOPD) is a common lung disease characterized by airflow limitation 
that is not fully reversible and is both chronic and progressive. AECOPD is a sudden worsening of COPD symptoms that typically lasts for several days. 
AECOPD readmission has been one of global concern and was the fifth leading cause of disease burden in Malaysia, both clinically and economically.
Objective: This study is aimed to screen the factors are contributed to readmission among AECOPD male patients in selected hospital of Malaysia and 
associated medication cost.
Methods: A cross-sectional study design was used in this study, whereby data collections were based on AECOPD Patient’s Medical Record that was 
readmitted to the male medical ward from January 1 to December 31, 2015, and documented into the patient’s data collection form. The collected data 
were analyzed using software name Statistical Package for Social Sciences version 17.0.
Results: Total sample population collected was 100 patients during the study period. Majority of patients aged from 50 to 79 years old (83%) and 74% 
of them were Malays. The 94% of them were associated with cigarette smoking and 93% were having concomitant disease of cardiovascular disorder 
and endocrine disorder. Out of 100 study population, 32% patients were readmitted back in more than 1 year since the previous hospitalization, while 
40% was readmitted back within <30 days. The longest day of hospitalization spent 12 days, but majority (56%) spent <5 days of hospitalization. 
Combinations between Augmentin and Azithromycin were the common (45%) antibiotics prescribed among the study population. Significantly 
statistical difference (p<0.05) is shown between cigarette smoking habits on different groups of age and between time readmission after discharge 
with medication adherence, while no significantly statistical difference (p>0.05) between the length of stay with medication cost during admission.
Conclusion: The readmission factors were contributed among AECOPD in selected hospital were revealed highest among Malay aged between 50 and 
79 years old, associated with cigarettes smoking and not adhere to medications. Medication cost during admission was not significantly increasing 
proportionally with the length of stay.
Keywords: Readmission, Chronic obstructive pulmonary disease, Acute exacerbation of chronic obstructive pulmonary disease, Medication cost.
INTRODUCTION
In developing countries, chronic respiratory diseases represent a 
challenge to public health because of their frequency, severity, projected 
trends, and economic impact. Health-care planners are faced with a 
dramatic increase in tobacco use and must establish priorities for the 
allocation of limited resources [1].
Chronic obstructive pulmonary disease (COPD) is a common lung 
disease characterized by airflow limitation that is not fully reversible 
and is both chronic and progressive [2]. Acute exacerbation of COPD 
(AECOPD) is associated with a significant increase in mortality, 
hospitalization, and health care utilization [3].
Inpatient admissions for COPD represent a significant economic burden, 
accounting for over half of direct medical costs. In Malaysia, the prevalence 
of COPD is moderate to severe, with approximately 448, 000 cases in the 
country, and the number of cases is consistently increasing year by year [4].
The interest in 30 days of readmission rates is growing worldwide. 
However, compared to the extensive studies that have been carried in the 
relation of readmission of COPD patients into the hospital in the US, there 
is very little study has been conducted in Malaysia regarding the hospital 
readmission among COPD patient within 30 days after discharged.
The aim of this study is to screen the factors contributed to readmission 




This study was approved by Medical Research Ethics Committee, 
Ministry of Health Malaysia with reference number [5] KKM/NIHSEC/
P16-314.
Study design and location
A cross-sectional and retrospective study design was performed in 
this study whereby data collection is based on the medical records 
of AECOPD patients readmitted into a male medical ward of hospital 
within 30 day from the hospital discharged. Collected data were from 
the patient’s medical records that were admitted from the January 1, 
2015, to December 31, 2015.
Exclusions and inclusions criteria
Study populations were registered cases of readmission with diagnosed 
AECOPD and readmitted into hospital within 30 days, more than 
30 days or <30 days after the previous discharged. Moreover, included 
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patients were Malaysian citizen with age above 21 years old. Excluded 
patients were not Malaysian citizen and pediatric.
Research tool and data analysis
Self-developed data collection form was used to record the data. 
Demographic data were recorded, such as age gender, race, BMI, family 
history, social history, and allergy. Signs and symptoms, including 
laboratory parameter, were recorded as well. Costs during admission 
were recorded too.
The collected data were processed statistically using Statistical Package 
for Social Sciences version 17.0, and frequency distribution was analyzed.
RESULTS
1. Sociodemographic (n=100)
 Majority (83%) of the study population belongs to age range of 
50-80 years with highest rate of readmission as well. However, 
among this age range (50 – 79 years) highest readmission is found 
among age group 60-69 years. Malay was the highest admissions 
into the hospital contributing to ¾ of the study population. Highest 
patients admitted due to COPD exacerbation are ex-chronic 
smokers (40%) followed by chronic smokers (35%).  A total of 6% 
of study populations were substance abusers (Table 1). There was 
a significant difference number that age group of 50-59 years old 
recorded as the highest chronic smokers while age group 60-69 
years old and 70-79 years old recorded as highest ex-chronic smokers 
(Table 2). Concomitant diseases presented, showed that 1/2 of the 
study population were having Cardiovascular disorders followed 
by Metabolic or Endocrine disorders (2/5). Respiratory disorders 
and renal disorders are 1/10 of the study population. A total of 
12% subjects are having other diseases such as Benign Prostate 
Hyperplasia (BPH) and Hepatitis C infection (Table 1).
2. Readmission status (n=88)
 Out of the total 100 subjects, 88 subjects were having recurrent 
admission, out of these 88 subjects; about 40% were having recurrent 
admissions within less than 30 days. Among those having recurrent 
admissions, it was found that more than 1/2 of them spent less than 
5 days of hospitalization (Table 3). 
 Half (1/2) of the study population was adhered to their medications. 
Out of those that adhere, more than 3/5 was found to have recurrent 
admission in more than 1 year since previous hospitalization. 
Only 4% was admitted for less than 30 days. There is a significant 
statistical difference numbers (p≤ 0.05) found between medication 
adherence and number of recurrent admission days (Table 6).
3. Clinical features (n=100)
 About 3/4 of study population came to Emergency Department with 
shortness of breath (SOB), 4/5 with symptoms of cough and 1/10 
came with fever and chest pain. More than half of study population 
showed peripheral haziness on their chest x-ray results (Table 
4). About 1/5 showed hyperinflated lungs, while 1/10 shows no 
pneumonic patches or changes. Only 4% of the study population 
showed emphysematous lungs.
4. Laboratory result on the first day of admission (n=100)
 Majority (≥ 50%) of study population experience increasing of 
systolic, diastolic, respiratory rate and WBC level on first day of 
admission (Table 5).
5. Culture and sensitivity result evaluation (n=100)
 Culture results of the study population showed that 97% came out 
as negative while only 3% were positive. Resistance to ampicillin/
sulbactam and ceftazidime recorded only 2%, the highest frequency 
in patients that having the positive result of C and S. Sensitivity 
test came out for tigecycline, doripenem, ertapenem, meropenem, 
imipenem with 1% occurrence each in a patient that was infected 
with multiple resistant organisms.
6. Medication adherence (n=100)
 About 100% received the management of COPD according to the 
guideline. 21% of the study population did not prescribe with an 
antibiotic, where 3 of them were discharged with old medications. 
The highest frequency of antibiotic administered to a patient in ED 































Table 2: Social history evaluation in different group of age 
among study population









30-39 1 0 0 2 0.00*
40-49 6 0 1 1
50-59 14 0 5 2
60-69 6 0 16 1
70-79 8 1 14 0
80-89 0 0 4 0
*Fisher exact test, p-value significant at ≤0.05
Table 3: Readmission status distribution among study 
population
Parameter Frequency (%)
Days of recurrent admission
<30 days 40
Within 30 days 5






Table 4: Clinical features distribution among study population
Parameter Frequency (%)
Chie complaint: SOB 78
Sign and symptoms: Cough 83
Chest X-ray: Peripheral haziness 66
SOB: Shortness of breath
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(79%) and in the ward (85%) was a combination of Augmentin and 
azithromycin.
7. Medication cost
 Daily medication cost for majority (9/10) of the study population 
was revealed to be less than RM300 while total cost during admission 
was less than RM 1,999 (Table 7). The estimated total medication 
cost evaluation on different length of hospital stay revealed that 
patient that spent more than 10 days of hospitalization spent a mean 
of RM2542.72±1833.17 on their total medication cost. Subjects 
that spent less than 5 days of hospitalization recorded lowest total 
medication cost with less than RM1000, with mean cost revealed to 
be around RM755.02±2524.45. There was no significant statistical 




The age distribution of study population was revealed to be highest 
in older population starting from age 50 years old until 79 years old. 
Majority of patients was Malay (74%), and 94% was associated with 
cigarette smoking, either as an ex-smoker or an active smoker. There is 
a significant difference (p<0.05) between the age group and smoking 
habit. The most dominating risk factors in AECOPD were increasing age 
and smoking habit, and it was estimated that half of the elderly smokers 
fulfilled the criteria for COPD according to both the BTS and the GOLD 
criteria [5].
Clinical features
Majority (3/4) of the study population came into the ED with chief 
complaints of shortness of breath (SOB). On assessment, majority of 
patients were diagnosed with a cough and flu (83%) and SOB (55%). 
Sputum was also one of accompanied symptoms among the study 
population (67%) ranging from whitish and yellowish sputum to 
greenish color sputum. A cough is often the first symptom of COPD 
which may initially be intermittent but later present on a daily basis, 
often with chronic sputum production. Wheezing and chest tightness 
may also be present [6].
All study population showed abnormalities in their chest X-ray results. 
Results showed that patient came with four types of abnormalities, 
such as peripheral haziness, hyperinflated lungs, emphysematous 
lungs, and no pneumonic patched lungs. Approximately 66% of the 
study population showed peripheral haziness, while only 10 patients 
showed no pneumonic changes on their lungs. Haziness is caused by 
increased absorption of the X-rays. Increased absorption occurred 
when tissues were denser, thicker, or had a higher fluid content than 
surrounding tissues. A diffuse haziness would typically be caused 
by inflammation or thickening of tissues, and there’s a variety of 
different causes and patterns. Emphysema was defined in terms of 
anatomic pathology. Emphysema historically was defined on histologic 
Table 5: Distribution of laboratory result on the first day of admission among study population
Parameter (normal range) n (%) Mean±SD
≤ Normal Within normal range ≥ Normal
Temperature (36.5-37.49°C) - 78 (78) 22 (22) 37.25±0.53
Systolic BP (90-119 mmHg) - 16 (16) 84 (84) 140.99±21.60
Diastolic BP (60-79 mmHg) 2 (2) 48 (48) 50 (55) 81.83±12.60
Heart rate (60-100 bpm) - 53 (53) 47 (947) 102.73±19.17
Respiratory rate (12-20 pm) - 33 (33) 67 (67) 28.29±12.55
SPO2 under RA (95-100) 62 (62) 38 (38) - 91.62±8.77
WBC (4.0-11.0×109/L) - 35 (35) 65 (65) 13.58±5.33
RBC (4.2-5.4×109/L) 15 (15) 74 (74) 11 (11) 6.17±10.61
pH (7.38-7.42) 45 (45) 28 (28) 27 (27) 7.36±0.97 
pCO2 (35-45 mmHg) 22 (22) 19 (19) 39 (39) 51.07±32.82
pO2 (38-42 mmHg) 2 (%) 5 (5) 93 (93) 124.89±59.89
HCO3 (22-28 mmol/L) 19 (19) 65 (65) 16 (16) 26.17±14.66
ALT (<32 IU/L) - 79 (79) 21 (21) 37.89±33.47
AST (10-40 IU/L) - 87 (87) 13 (13) 12.03±6.99
Urea (1.7-8.3 mmol/L) 83 (83) 17 (17) 6.10±3.08
Creatinine (64-122 umol/L) 13 (13) 74 (74) 13 (13) 94.92±62.36
Na (135-145 mmol/L) 19 (19) 80 (80) 1 (1) 137.08±5.33
K (3.5-5.0 mmol/L) 24 (24) 70 (70) 6 (6) 3.95±0.67
SD: Standard deviation, RBC: Red blood cell, WBC: White blood cell
Table 6: Medication adherence evaluation among study 
population
Recurrent admission days Medication adherence p‑value
Yes No
n (%) n (%)
<30 days 4 36 
Within 30 days 0 5 0.000*
>30 days - 1 year 17 6 
>1 year 31 1
*Chi-square test, p-value significant at ≤0.05















Table 8: Medication cost distribution among study population
Length of stay Cost (RM) p‑value
Mean±SD
<5 days 755.02±2524.45
5-10 days 1280.06±920.54 0.742*
>10 days 2542.72±1833.17
*Fisher exact test, p-value significant at ≤0.05, SD: Standard deviation
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examination at autopsy. Due to this histologic definition is of limited 
clinical value, emphysema also has been defined as an abnormal 
permanent enlargement of the airspaces distal to the terminal 
bronchioles, accompanied by destruction of their walls yet without 
obvious fibrosis [2].
Laboratory result on the first day of admission
More than 62% of the study population had a reduction in the SPO2 level 
with a mean reading of 91.62±8.77%. The most significant parameter in 
full blood count for diagnosis of COPD is white blood cell (WBC) level. 
More than 65% of the study population was presented with elevated 
WBC count with a mean reading of 13.58×109/L±5.33.
Arterial blood gas analysis provides the best clues as to acuteness 
and severity of disease exacerbation [7]. In a patient experiencing a 
severe exacerbation, profound hypoxemia and hypercapnia can be 
accompanied by respiratory acidosis and respiratory failure [2].
Culture and sensitivity result evaluation
Since only three incidences of AECOPD were associated with positive C 
and S, and no specific pathogens were mentioned in patient’s medical 
records, therefore it could not be concluded that readmission of AECOPD 
patients due to the bacterial infection. The highest incidence (2%) of 
antibiotic resistance was against ampicillin/sulbactam (Unasyn) and 
ceftazidime. Antibiotic resistance increased in all major pathogens. 
The patients’ having antibiotic resistance against ceftazidime was not 
given this antibiotic in his empirical treatment, and so the occurrence 
of antibacterial resistance was avoided.
Medication profile evaluation
The majority of the study population (79%) received antibiotic 
treatment in ED. Antibiotic administration in ED was given as empirical 
treatment if a patient came with either two of these symptoms 
increased a cough and sputum volume, purulent sputum and/or 
increased dyspnea [6]. Result of this study showed that combination 
of Augmentin (amoxicillin/clavulanate acid) and azithromycin is the 
most frequently initial antibiotic administered in ED for AECOPD. 
Even though the administration of initial antibiotic in ED serves as 
empirical treatment, the efficacy of antibiotic therapy in AECOPD is still 
controversial and has been the focus of an extensive review [8].
Medication cost
Estimated daily medication cost shows that 38% of the study population 
spent less than RM100 per day, while only 3% spent between RM500 
and RM599. According to Dalal et al., the cost of medication increased 
with people having complex AECOPD or in people requiring invasive 
intubation [9]. However, no studies are conducted in Malaysia in 
relation to medication cost for readmitted AECOPD patients, therefore 
no generalization of medication cost could be made.
Patients spent more than 10 days of hospitalization were seen having 
the highest mean cost of RM2542.72 while those who spent <5 days of 
hospitalization recorded the lowest mean cost of RM755.02 total cost of 
medication. There is no significant statistical difference value between 
the length of stay and total cost of medication. However, one study in 
2010 by Dalal et al., showed that the costs of hospital-based care for 
COPD are substantial. Admissions involving intubation or intensive care 
are associated with the highest costs, length of stay and mortality [9].
CONCLUSION
The distribution of the population of COPD patients readmitted in 
selected hospital was higher among Malays and of those within the age 
group of 50-79 years old. Most patients included in this study have a 
social history as an ex-chronic smoker which is the leading cause of 
exacerbation of COPD. All patients of COPD received treatment in the 
hospital according to the management stated in the clinical practice 
guideline for COPD provided by MOH. Majority of patients received 
antibiotic treatment in ED as empirical treatment. The highest usage 
for antibiotic was revealed to be the combination of Augmentin and 
Azithromycin. There was a significant increment of time readmission 
after discharge due to nonadherence to medication. Even though there 
is no significant difference between total costs of medication with the 
length of stay in the hospital, there is an increased trend of longer 
hospitalization observed that will subsequently result with higher 
medication cost.
ACKNOWLEDGMENT
Authors are thankful to all the lecturers of School of Pharmacy, 
Management and Science University, Malaysia, for providing support 
and knowledge throughout this study and also to the hospital for 
allowing to carry out this study at their premises.
REFERENCES
1. Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases 
in developing countries: The burden and strategies for prevention and 
management. Bull World Health Organ 2001;79(10):971-9.
2. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 
Pharmacotherapy: A Pathophysiologic Approach. New York: 
McGraw-Hill Companies; 2011. p. 495-6.
3. Rodriguez-Roisin R. Toward a consensus definition for COPD 
exacerbations. Chest J 2000;117 Suppl 5:398S-401.
4. Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific 
countries and regions: Projections based on the COPD prevalence 
estimation model. Respirology 2003;8(2):192-8.
5. Lundback B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, 
Jönsson E, et al. Not 15 but 50% of smokers develop COPD? Report 
from the obstructive lung Disease in Northern Sweden studies. Respir 
Med 2003;97 Suppl 2:115-22.
6. Ministry of Health Malaysia. Clinical practice guidelines. Management 
of Chronic Obstructive Pulmonary Disease. 2nd ed. Malaysia: Academy 
of Medicine of Malaysia, Malaysian Thoracic Society; 2009. p. 1-67.
7. Cosimo MB, Maria V. Acid-base disorders in patients with chronic 
obstructive pulmonary disease: A pathophysiological review. J Biomed 
Biotechnol 2012;2012:1-8.
8. Adams SG, Jairo M, Michael L, Antonio A. Antibiotics are associated 
with lower relapse rates in outpatients with acute exacerbations of 
COPD. Chest J 2000;117 Suppl 5:1345-52.
9. Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD exacerbations 
in the emergency department and inpatient setting. Respir Med 
2011;105 Suppl 3:454-60.
